3-氨基-5-氟吡啶 | 210169-05-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基-5-氟吡啶
• 英文名称: 5-fluoropyridin-3-amine
• 英文别名: 3-amino-5-fluoropyridine；3-fluoro-5-aminopyridine
• CAS: 210169-05-4
• 化学式: C₅H₅FN₂
• mdl: MFCD00234073
• 分子量: 112.107
• InChiKey: ZRORIJXOWXYPMO-UHFFFAOYSA-N

物化性质

• 熔点：
  86°C
• 沸点：
  232.7±20.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2933399090
• 危险标志：
  GHS07
• 危险性描述：
  H302,H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Fluoropyridin-3-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Fluoropyridin-3-amine
CAS number: 210169-05-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H5FN2
Molecular weight: 112.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

3-氨基-5-氟吡啶是一种白色结晶固体，是众多吡啶衍生物中较为突出的中间体。由于其良好的生物活性，在医药和农药合成领域有着重要的应用价值，常被用作重要原料或关键中间体。在吡啶类药物的合成过程中，它发挥着重要作用。

用途

3-氨基-5-氟吡啶作为重要的工业原料，在医药、农药及染料等行业中广泛应用。由于吡啶环具有显著的生物活性，在药物合成方面难以被其他基团或官能团替代，因此在医药研究领域是一个热点话题。

在医药领域，3-氨基-5-氟吡啶及其衍生物广泛用于合成多种重要药物，包括泮托拉唑钠（治疗十二指肠溃疡）、SB-243213（抗抑郁药）、维生素B6（缓解妊娠呕吐）、溴地斯的明（支气管扩张剂）、吡布特罗（治疗慢性阻塞性肺病）、吡罗昔康（关节炎药物）和帕潘利酮（精神类药物）。而在染料领域，3-氨基-5-氟吡啶主要用于合成偶氮化合物的偶合剂。例如，4-硝基-2-氨基-1-羟基苯与2-氨基-3-羟基吡啶反应生成的是吡啶酮类染料。

反应信息

• 作为反应物：
  描述：

  3-氨基-5-氟吡啶 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 (R)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthyl 作用下， 以 正庚烷 、 2,2,2-三氟乙醇 、 乙酸甲酯 、 甲苯 为溶剂， 生成 艾伏尼布
  参考文献：
  名称：

  [EN] SOLID STATE FORMS OF IVOSIDENIB
  [FR] FORMES À L'ÉTAT SOLIDE D'IVOSIDÉNIB

  摘要：

  Ivosidenib的固态形式、其制备方法、其药物组合物和用途均已披露。

  公开号：

  WO2019104318A1
• 作为产物：
  描述：

  2,6-二氯-5-氟烟酸 在 ammonium hydroxide 、 氯化亚砜 、 palladium on activated charcoal 、 氢气 、 溴 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 反应 23.0h， 生成 3-氨基-5-氟吡啶
  参考文献：
  名称：

  一种5-氟-3-氨基吡啶的制备方法

  摘要：

  本发明公开了一种5‑氟‑3‑氨基吡啶的制备方法，属于吡啶类化合物技术领域，其特点包括如下操作步骤：将5‑氟烟酰胺滴加到次卤酸盐溶液内，再在0‑100℃下搅拌直至TLC反应完成；降至室温后加入氢氧化钠溶液，继续搅拌20‑40min，过滤烘干后得到5‑氟‑3‑氨基吡啶固体。本发明不仅操作工艺安全，简单方便，生产设备要求不高，而且在保证产品质量和良好的产率的基础上，适合放大生产。

  公开号：

  CN109678793B

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I<br/>[FR] MODULATEURS DU RÉCEPTEUR Alpha7 NICOTINIQUE D'ACÉTYLCHOLINE ET LEURS UTILISATIONS
  申请人：BIONOMICS LTD

  公开号：WO2014019023A1

  公开（公告）日：2014-02-06

  The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.

  本发明涉及化学式（I）的化合物，其取代基如规范中所述，在正向调节α7尼古丁乙酰胆碱受体（α7 nAChR）中有用。该发明还涉及这些化合物在治疗或预防广泛范围的疾病中的应用，其中正向调节α7 nAChR是有利的，包括神经退行性和神经精神疾病，以及神经病性疼痛和炎症性疾病。
• Visible-Light-Driven Synthesis of Arylstannanes from Arylazo Sulfones
  作者：Chang Lian、Guanglu Yue、Jinshan Mao、Danyang Liu、Yi Ding、Zerong Liu、Di Qiu、Xia Zhao、Kui Lu、Maurizio Fagnoni、Stefano Protti

  DOI：10.1021/acs.orglett.9b01788

  日期：2019.7.5

  The visible-light-driven preparation of (hetero)aryl stannanes was carried out under both photocatalyst- and metal-free conditions via irradiation of arylazo sulfones in the presence of hexaalkyldistannanes. The reaction shows a high efficiency and a wide substrates scope. The resulting crude organotin derivatives can be directly employed in a Stille protocol.

  （杂）芳基锡烷的可见光驱动制备是在六烷基二锡烷存在下，通过芳基偶氮砜的辐射，在无光催化剂和无金属的条件下进行的。该反应显示出高效率和广泛的底物范围。所得的粗有机锡衍生物可以直接用于Stille方案中。
• 由取代的芳基胺转化为芳基偶氮甲基砜的方法
  申请人：天津师范大学

  公开号：CN113024430A

  公开（公告）日：2021-06-25

  本发明公开了一种由取代的芳基胺转化为芳基偶氮甲基砜的方法，方法包括以下步骤：将芳基胺、亚硝酸钠和四氟硼酸水溶液混合均匀，在0‑5℃下反应1～2小时，过滤以去除水，得到固体的芳基重氮盐，再将所述芳基重氮盐、甲基亚磺酸钠和溶剂混合均匀，在0‑5℃下反应8～12小时，过滤以去除不溶固体，浓缩过滤所得滤液，以通过重结晶得到固体的芳基偶氮甲基砜，本发明直接采用四氟硼酸水溶液中的水作为第一步的反应溶剂，以及采用1,2‑二氯乙烷作为第二步的溶剂，能够很好的改进目前芳基偶氮甲基砜制备方法产率较低的问题。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ NLRP
  申请人：IFM TRE INC

  公开号：WO2019023145A1

  公开（公告）日：2019-01-31

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一个方面，特色化合物AA的公式，或其药学上可接受的盐。在公式AA中显示的变量如索引中所定义。公式AA的化合物是NLRP3活性调节剂，因此可用于治疗代谢性疾病（例如2型糖尿病、动脉粥样硬化、肥胖或痛风）、中枢神经系统疾病（例如阿尔茨海默病、多发性硬化症、肌萎缩性侧索硬化或帕金森病）、肺部疾病（例如哮喘、慢性阻塞性肺疾病或肺部特发性纤维化）、肝脏疾病（例如NASH综合征、病毒性肝炎或肝硬化）、胰腺疾病（例如急性胰腺炎或慢性胰腺炎）、肾脏疾病（例如急性肾损伤或慢性肾损伤）、肠道疾病（例如克罗恩病或溃疡性结肠炎）、皮肤疾病（例如牛皮癣）、肌肉骨骼疾病（例如硬皮病）、血管障碍（例如巨细胞动脉炎）、骨骼疾病（例如骨关节炎、骨质疏松症或骨质增生疾病）、眼部疾病（例如青光眼或黄斑变性）、病毒感染引起的疾病（例如HIV或艾滋病）、自身免疫疾病（例如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。

表征谱图